EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

Rhea-AI Summary

BD (NYSE: BDX) and EMS, a leading Brazilian pharmaceutical company, announced a collaboration to launch an EMS semaglutide therapy in Brazil using the BD Vystra™ Injection Pen platform. The partnership aims to improve access to GLP‑1 treatments for chronic metabolic diseases such as obesity and type 2 diabetes.

According to BD, the Vystra pen offers an intuitive, research-backed design to support safe, accurate and consistent self-injection, addressing patient challenges with ease of use, confidence and adherence. EMS highlights that co-creation with BD helps meet the needs of Brazilian clinicians and patients.

News Market Reaction – BDX

+1.24%

+1.24% Session close to close

In the Jul 29 session, BDX gained 1.24%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

BDX's historical news reactions included 2.28% after a contract award and -0.48% after a product lau...

Analysis

BDX's historical news reactions included 2.28% after a contract award and -0.48% after a product launch. That mixed record frames this partnership as an access milestone, with low short positioning and net selling as separate watchpoints.

Key Figures

Announcement date: July 29, 2026 BD employees: More than 60,000 employees EMS experience: More than 60 years +2 more

5 metrics

Announcement date July 29, 2026 Semaglutide collaboration announcement

BD employees More than 60,000 employees Company description

EMS experience More than 60 years EMS company description

EMS global footprint More than 60 countries EMS company description

Annual product volume Billions of products annually BD company description

Historical Context

5 past events · Latest: Jul 22 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 22	Leadership retirement	Negative	-0.4%	Executive retirement announced with successor search and operating-model changes
Jul 09	Earnings scheduling	Neutral	+0.7%	Third-quarter fiscal 2026 results webcast scheduled for August 6
Jun 23	Contract award	Positive	+2.3%	Vizient awarded Innovative Technology contract for CentroVena One system
May 21	Product launch	Positive	-0.5%	Elyra Thulium Fiber Laser System introduced for urology procedures
May 18	Leadership appointment	Positive	-0.8%	Peter Menziuso appointed EVP and president of BD Interventional

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

BDX's recent news record was mixed: two positive operational announcements were followed by declines, while a contract award was followed by a gain.

Key Terms

glp‑1 therapies, semaglutide, self-injection

3 terms

glp‑1 therapies medical

"Global demand for GLP‑1 therapies has highlighted the critical need"

GLP-1 therapies are medicines that mimic or boost the natural hormone glucagon-like peptide-1, which helps the body release insulin, slow stomach emptying, and reduce appetite; they are commonly used to treat type 2 diabetes and obesity. They matter to investors because strong clinical results and rising demand can drive significant sales, change healthcare costs and coverage, and ripple through drugmakers, insurers and suppliers—like a breakthrough product that reshapes several markets.

semaglutide medical

"today announced their collaboration in the launch of a semaglutide therapy"

Semaglutide is a medication originally developed to help manage blood sugar levels in people with diabetes, but it also promotes weight loss. It works by mimicking a natural hormone that helps control appetite and insulin release. For investors, its potential to influence healthcare and weight management markets makes it a significant product in the pharmaceutical industry.

self-injection medical

"confidence with self‑injection and adherence to treatment"

A method of giving a drug where the patient or caregiver injects the medicine themselves, usually with a prefilled syringe, pen or autoinjector outside a clinic. Think of it like an insulin or emergency injection device that lets people take medicines at home. It matters to investors because self-injection affects a drug’s convenience, patient adoption, recurring use, regulatory and reimbursement pathways, manufacturing needs, and potential market size.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

 Collaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.

FRANKLIN LAKES, N.J. and SÃO PAULO, July 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, today announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes.

Global demand for GLP‑1 therapies has highlighted the critical need for delivery systems that enable safe, accurate, and consistent dosing for patients. Many patients face challenges with ease of use, confidence with self‑injection and adherence to treatment, making intuitive and reliable delivery solutions increasingly important.

EMS's semaglutide utilizes BD's established injection pen platform, which features an intuitive design built for ease of use. The BD Vystra™ Injection Pen platform reflects BD's deep expertise in drug delivery systems design and manufacturing, supporting scalable solutions that can help meet rising demand for injectable therapies.

"BD's partnership with EMS introduces a critical treatment option backed by scalable, patient-centric delivery technology," said Patrick Jeukenne, Worldwide President of Pharmaceutical Systems at BD. "By combining this therapy with BD's established pen platform, patients benefit from a proven, research backed design that supports usability for self-injection."

"Launching our semaglutide marks an important step in expanding access to advanced metabolic therapies in Brazil," said Gabriel Sanchez, Vice President of EMS. "By co-creating with BD, we're able to provide solutions that meet the needs of our clinicians and patients alike."

About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at  www.linkedin.com/company/bd1/, X   or Instagram @becton_dickinson.

About EMS
EMS is one of Brazil's leading pharmaceutical companies, with more than 60 years of experience developing and delivering innovative, high-quality therapies. The company operates across prescription medicines, generics and OTC, with a growing global footprint spanning more than 60 countries. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies for obesity and type 2 diabetes.

Contacts:
Media	Investors
Matt Marcus VP, Public Relations Matt.Marcus@bd.com	Shawn Bevec  SVP, Investor Relations Investor_Relations@bd.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ems-and-bd-expand-access-to-glp-1-therapies-in-brazil-with-semaglutide-launch-302837695.html

SOURCE BD (Becton, Dickinson and Company)

FAQ

What did BD (NYSE: BDX) announce about semaglutide and EMS in Brazil on July 29, 2026?

BD announced a collaboration with EMS to launch an EMS semaglutide therapy in Brazil using the BD Vystra Injection Pen. According to BD, this partnership focuses on expanding access to GLP‑1 metabolic therapies and improving self-injection usability for obesity and type 2 diabetes patients.

How does the BD Vystra Injection Pen support EMS semaglutide therapy for GLP-1 treatment?

The BD Vystra Injection Pen provides an intuitive, research-backed platform for delivering EMS semaglutide therapy. According to BD, the pen is designed to support safe, accurate, and consistent dosing, addressing patient challenges with ease of use, self-injection confidence, and adherence in GLP‑1 treatment.

What patient needs are BD and EMS targeting with the semaglutide launch in Brazil (BDX)?

BD and EMS are targeting patients with chronic metabolic diseases, including obesity and type 2 diabetes. According to BD, the collaboration addresses needs around safe, accurate GLP‑1 dosing, ease of self-injection, treatment confidence, and adherence through the BD Vystra Injection Pen platform.

Why is the BD and EMS semaglutide collaboration important for GLP-1 access in Brazil?

The collaboration is intended to expand access to advanced GLP‑1 metabolic therapies in Brazil by pairing EMS semaglutide with BD’s Vystra pen. According to BD and EMS, scalable, patient-centric delivery technology can help meet rising demand and support clinicians’ and patients’ treatment needs.

Does the BD (BDX) and EMS semaglutide agreement include any specific financial terms or revenue figures?

The announcement does not disclose any specific financial terms, revenue figures, or contract values for the BD and EMS semaglutide collaboration. According to BD, the focus of the release is on expanding access, leveraging the Vystra pen platform, and supporting patient-centric GLP‑1 delivery in Brazil.